Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407004 | 0.87 | CTRB1 (0.40) | ALDH1A1 | |
| SCHEMBL30510366 | 0.87 | CTRB1 (0.40) | ALDH1A1 | |
| SCHEMBL4600752 | 0.87 | CTRB1 (0.40) | ALDH1A1 | |
| SCHEMBL4600067 | 0.87 | CTRB1 (0.40) | ALDH1A1 | |
| SCHEMBL4034324 | 0.87 | PPARG (0.41) | MMP1KMT2AMEN1 | |
| SCHEMBL4034320 | 0.87 | PPARG (0.41) | MMP1KMT2AMEN1 | |
| SCHEMBL4600010 | 0.87 | LDHA (0.47) | LDHAKMT2AFPR2 | |
| SCHEMBL30510242 | 0.87 | LDHA (0.47) | LDHAKMT2AFPR2 | |
| SCHEMBL4183822 | 0.86 | PIN1 (0.36) | LDHAMMP1 | |
| SCHEMBL25183036 | 0.86 | RAB9A (0.43) | MMP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641795-B1 | TRIAZA- AND TETRAAZA-ANTHRACENEDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-7132536-B2 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-07 | — | — | US | disclosed |
| EP-1641795-A1 | TRIAZA- AND TETRAAZA-ANTHRACENEDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248900-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004094425-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | WO | disclosed |
| EP-1471066-A1 | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248900-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | CYP19A1, TBXAS1, CYP11B1 | LDHA 2225/4885MMP1 1031/4885KMT2A 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.